Skip to main content
. 2015 Mar 11;7(2):352–363. doi: 10.1080/19420862.2015.1007828

Figure 6.

Figure 6.

In vitro characterization of engineered anti-IFNγ antibody variants – (A) product titer measured post Protein A purification (in mg/ml), (B) percentage of monomer, (C) binding affinity log(EC50) (EC50 in pM).